New immunotherapy could avoid bladder removal
An advanced clinical study has demonstrated that a new immunotherapy prevents the need for bladder removal in patients with high-grade bladder cancer. Tendo, the treatment administered instead of surgery, allows patients to preserve their bladder function and results in a complete cancer response in 75% of cases, with those responses lasting for over two years in approximately 60% of patients. Developed by C.G. Oncology, the therapy has successfully prevented cancer recurrence for more than four years in some cases, enhancing patients' quality of life and reducing surgical interventions.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading